Cover Image
市場調查報告書

痛風性關節炎 (痛風) :開發中產品分析

Gouty Arthritis (Gout) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232848
出版日期 內容資訊 英文 105 Pages
訂單完成後即時交付
價格
Back to Top
痛風性關節炎 (痛風) :開發中產品分析 Gouty Arthritis (Gout) - Pipeline Review, H2 2016
出版日期: 2016年11月16日 內容資訊: 英文 105 Pages
簡介

痛風是關節炎的一種,會讓血液中積存尿酸,並在關節發炎的疾病。主要症狀有發病部分的關節腫脹,其週邊皮膚發熱並僵硬化,還會發紅並帶光澤,會突然感到激痛,關節脆弱等。致病因子有肥胖及酗酒、關節部分外傷、長期腎臟疾病、攝取過多含有普林的食物等。主要治療方法有非甾體抗炎藥物(NSAID)等。

本報告提供全球各國治療痛風性關節炎 (痛風) 所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

痛風性關節炎 (痛風)的概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

痛風性關節炎 (痛風) :企業開發中的治療藥

痛風性關節炎 (痛風) :大學/機關研究中的治療藥

痛風性關節炎 (痛風) :開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

痛風性關節炎 (痛風) :企業開發中的產品

痛風性關節炎 (痛風) :大學/機關研究中的產品

痛風性關節炎 (痛風)治療藥的開發企業

  • AstraZeneca Plc
  • Celtaxsys, Inc.
  • CymaBay Therapeutics, Inc.
  • Delenex Therapeutics AG
  • Immune Response BioPharma, Inc.
  • IOmet Pharma
  • JW Pharmaceutical Corporation
  • LG Life Science LTD.
  • Monosol Rx, LLC
  • Nimbus Therapeutics, LLC
  • Opsona Therapeutics Limited
  • Polaris Pharmaceuticals, Inc.
  • ProteoThera, Inc.
  • Swedish Orphan Biovitrum AB
  • 武田藥品工業
  • TEIJIN FIBERS製藥
  • TWi Pharmaceuticals, Inc.
  • Wellstat Therapeutics Corporation

痛風性關節炎 (痛風) :治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

痛風性關節炎 (痛風) :最近的開發平台趨勢

痛風性關節炎 (痛風) :暫停中的計劃

痛風性關節炎 (痛風) :開發中止的產品

痛風性關節炎 (痛風) :產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8672IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gouty Arthritis (Gout) - Pipeline Review, H2 2016, provides an overview of the Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline landscape.

Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gouty Arthritis (Gout) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 8, 3, 14, 4 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Gouty Arthritis (Gout).

Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gouty Arthritis (Gout) Overview
  • Therapeutics Development
    • Pipeline Products for Gouty Arthritis (Gout) - Overview
    • Pipeline Products for Gouty Arthritis (Gout) - Comparative Analysis
  • Gouty Arthritis (Gout) - Therapeutics under Development by Companies
  • Gouty Arthritis (Gout) - Therapeutics under Investigation by Universities/Institutes
  • Gouty Arthritis (Gout) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Gouty Arthritis (Gout) - Products under Development by Companies
  • Gouty Arthritis (Gout) - Products under Investigation by Universities/Institutes
  • Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development
    • Allena Pharmaceuticals, Inc.
    • AstraZeneca Plc
    • C&C Research Laboratories
    • Cell Medica Limited
    • Immune Response BioPharma, Inc.
    • IOmet Pharma
    • Jiangsu Hengrui Medicine Co., Ltd.
    • LG Life Science LTD.
    • Monosol Rx LLC
    • Nimbus Therapeutics, LLC
    • Opsona Therapeutics Limited
    • Polaris Pharmaceuticals, Inc.
    • ProteoThera, Inc.
    • Selvita S.A.
    • Swedish Orphan Biovitrum AB
    • Teijin Pharma Limited
    • TWi Pharmaceuticals, Inc.
    • Wellstat Therapeutics Corporation
    • XL-protein GmbH
  • Gouty Arthritis (Gout) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALLN-346 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • anakinra - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APP-112 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AQB-565 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AXIBU-03 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • colchicine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diacerein - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DLX-2323 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DLX-2681 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • febuxostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-888 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LC-350189 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation and Respiratory Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ND-2110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ND-2158 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ND-346 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegadricase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRT-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Enzyme for Gout and Tumor Lysis Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REV-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RLBN-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SEL-212 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHR-4640 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule Inflammasome Modulator Programme - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit GLUT9 for Gout - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TMX-049 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • URC-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • uriSHELS - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • verinurad - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WT-2107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XEN-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XEN-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XL-400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Gouty Arthritis (Gout) - Dormant Projects
  • Gouty Arthritis (Gout) - Discontinued Products
  • Gouty Arthritis (Gout) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 26, 2016: Selecta Biosciences Initiates Phase 2 Clinical Trial of SEL-212, First Non-Immunogenic Biologic in Development for Treatment of Gout
      • Jun 27, 2016: TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment
      • May 10, 2016: Revive Therapeutics Provides Clinical and Corporate Update
      • Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra)
      • Mar 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra)
      • Dec 24, 2015: TWi Biotechnology Reports Positive Interim Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients
      • Dec 23, 2015: Selecta Biosciences Announces Dosing of First Patient in Phase 1b Clinical Trial of SEL-212, Designed to be the First Non-Immunogenic Biologic Treatment for Gout
      • Oct 19, 2015: MonoSol Rx Leadership Presents Data Supporting PharmFilm Technology Effective for Oral Peptide Delivery
      • Sep 30, 2015: Revive Therapeutics Announces Positive Interim Results From Phase 2a Study of REV-002 in the Treatment of Acute Gout Flares
      • Jun 30, 2015: New Indication for Teijin Pharma's Febuxostat in Europe
      • Jun 10, 2015: Selecta Biosciences Initiates Phase 1 Clinical Program of SEL-212, Designed As the First Non-Immunogenic Biologic Treatment for Gout
      • Feb 27, 2015: Stiris Research Awarded a Phase IIa Trial in Gout
      • Feb 26, 2015: Revive Therapeutics Expands its Orphan Drug Indication Pipeline to Include Cystinuria and Wilson Disease
      • Dec 12, 2014: TWi Biotechnology Receives Approval of Protocol for Its Drug AC-201 Controlled-Release Tablet, Phase II Clinical Trial in Both the United States and Taiwan
      • Nov 26, 2014: Revive Therapeutics Announces US FDA Acceptance of IND to Commence Clinical Trial for Bucillamine for the Treatment of Gout
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Gouty Arthritis (Gout), H2 2016
  • Number of Products under Development for Gouty Arthritis (Gout) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Gouty Arthritis (Gout) - Pipeline by Allena Pharmaceuticals, Inc., H2 2016
  • Gouty Arthritis (Gout) - Pipeline by AstraZeneca Plc, H2 2016
  • Gouty Arthritis (Gout) - Pipeline by C&C Research Laboratories, H2 2016
  • Gouty Arthritis (Gout) - Pipeline by Cell Medica Limited, H2 2016
  • Gouty Arthritis (Gout) - Pipeline by Immune Response BioPharma, Inc., H2 2016
  • Gouty Arthritis (Gout) - Pipeline by IOmet Pharma, H2 2016
  • Gouty Arthritis (Gout) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
  • Gouty Arthritis (Gout) - Pipeline by LG Life Science LTD., H2 2016
  • Gouty Arthritis (Gout) - Pipeline by Monosol Rx LLC, H2 2016
  • Gouty Arthritis (Gout) - Pipeline by Nimbus Therapeutics, LLC, H2 2016
  • Gouty Arthritis (Gout) - Pipeline by Opsona Therapeutics Limited, H2 2016
  • Gouty Arthritis (Gout) - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016
  • Gouty Arthritis (Gout) - Pipeline by ProteoThera, Inc., H2 2016
  • Gouty Arthritis (Gout) - Pipeline by Selvita S.A., H2 2016
  • Gouty Arthritis (Gout) - Pipeline by Swedish Orphan Biovitrum AB, H2 2016
  • Gouty Arthritis (Gout) - Pipeline by Teijin Pharma Limited, H2 2016
  • Gouty Arthritis (Gout) - Pipeline by TWi Pharmaceuticals, Inc., H2 2016
  • Gouty Arthritis (Gout) - Pipeline by Wellstat Therapeutics Corporation, H2 2016
  • Gouty Arthritis (Gout) - Pipeline by XL-protein GmbH, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Gouty Arthritis (Gout) - Dormant Projects, H2 2016
  • Gouty Arthritis (Gout) - Dormant Projects (Contd..1), H2 2016
  • Gouty Arthritis (Gout) - Dormant Projects (Contd..2), H2 2016
  • Gouty Arthritis (Gout) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Gouty Arthritis (Gout), H2 2016
  • Number of Products under Development for Gouty Arthritis (Gout) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top